Incorporating New Therapies to Hone the Treatment of Resistant or Refractory CMV in the Post-SOT Setting: Proceedings from a Clinical Olympics℠
Program Overview
Join Drs. Kotton, Pereira, and Razonable as they discuss the management of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. Topics covered include treatment challenges, laboratory testing, and new therapy for refractory or resistant CMV.
Infectious disease, transplantation, internal medicine, and pharmacy clinicians managing patients with CMV
Educational Objectives
Upon completion of this activity, participants should be better able to:
Apply treatment strategies with established antiviral therapies to solid organ transplant (SOT) recipients who develop cytomegalovirus (CMV) in the post-transplant setting
Identify SOT recipients who develop treatment-resistant or refractory CMV in the post-transplant setting
Integrate new antiviral therapies into management regimens for resistant or refractory CMV in the post-SOT setting
Activity Faculty
Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital Associate Professor, Medicine
Harvard Medical School
Boston, MA
Marcus R. Pereira, MD, MPH, FAST
Associate Professor, Medicine Medical Director, Transplant Infectious Diseases Program
Columbia University Irving Medical Center
NewYork Presbyterian Hospital
New York, NY
Raymund R. Razonable, MD, FIDSA, FAST
Professor, Medicine Program Director, Infectious Diseases Fellowship Program Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, MN